Armenian H K, Hoover D R, Rubb S, Metz S, Kaslow R, Visscher B, Chmiel J, Kingsley L, Saah A
Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD.
Am J Epidemiol. 1993 Aug 15;138(4):256-65. doi: 10.1093/oxfordjournals.aje.a116854.
The possibility that an agent in addition to human immunodeficiency virus type 1 may be involved in the etiology of Kaposi's sarcoma in acquired immunodeficiency syndrome (AIDS) patients was investigated between 1984 and 1992 in this nested case-control analysis from the Multicenter AIDS Cohort Study (MACS) of homosexual and bisexual men. A total of 316 cases of Kaposi's sarcoma were identified and compared with 510 participants with AIDS and no evidence of cancer. More of the Kaposi's sarcoma cases were from Los Angeles and used a higher number of recreational drugs. The Kaposi's sarcoma cases were also more active sexually. There was a dose-response relation between Kaposi's sarcoma and the number of sexual partners, with an odds ratio of 2 between the most and least sexually active subgroups. The odds ratio for Kaposi's sarcoma increased to 4.18 (95% confidence interval 1.29-14.1) in the presence of a history of five infections. Hepatitis and gonorrhea contributed the most to this relation. The various observed odds ratios did not change after multivariate adjustment for the other risk factors. A model was developed combining all predictive associations into a composite risk score ranging from one to 12 and based on history of infections, sexual activity, use of poppers/nitrites, and having had sexual partners from the West Coast of the United States. The subgroup with the highest scores, compared to the subgroup with the lowest score, had an odds ratio of 8.93 (95% confidence interval 3.21-30.44) for Kaposi's sarcoma. A longitudinal proportional hazards analysis among all 2,190 human immunodeficiency virus type 1-seroprevalent men at study entry, based on this risk score and CD4 cells at baseline, confirmed these findings. Identifying these specific subgroups that are at high and low risk for Kaposi's sarcoma will help future investigations to be more focused in their search for an additional etiologic factor for Kaposi's sarcoma in AIDS.
1984年至1992年间,在这项针对同性恋和双性恋男性的多中心艾滋病队列研究(MACS)的巢式病例对照分析中,研究了除1型人类免疫缺陷病毒外,可能还有其他因素参与获得性免疫缺陷综合征(AIDS)患者卡波西肉瘤病因的可能性。共识别出316例卡波西肉瘤病例,并与510名患有AIDS且无癌症证据的参与者进行比较。更多的卡波西肉瘤病例来自洛杉矶,且使用的娱乐性药物数量更多。卡波西肉瘤病例的性活动也更活跃。卡波西肉瘤与性伴侣数量之间存在剂量反应关系,性活动最活跃和最不活跃的亚组之间的比值比为2。在有五次感染史的情况下,卡波西肉瘤的比值比增至4.18(95%置信区间1.29 - 14.1)。肝炎和淋病对这种关系的影响最大。在对其他风险因素进行多变量调整后,各种观察到的比值比没有变化。开发了一个模型,将所有预测关联组合成一个从1到12的综合风险评分,该评分基于感染史、性活动、使用Poppers/亚硝酸盐以及有来自美国西海岸的性伴侣。与得分最低的亚组相比,得分最高的亚组患卡波西肉瘤的比值比为8.93(95%置信区间3.21 - 30.44)。在研究开始时对所有2190名1型人类免疫缺陷病毒血清阳性男性进行的纵向比例风险分析,基于该风险评分和基线时的CD4细胞,证实了这些发现。识别这些卡波西肉瘤高风险和低风险的特定亚组,将有助于未来的研究更有针对性地寻找AIDS患者卡波西肉瘤的其他病因。